CJC-1295 No DAC & Ipamorelin Research Lab Setup Guide

Setting up a research workflow around CJC-1295 no DAC and ipamorelin is mostly a sourcing and documentation exercise, not an equipment one. Before any bench hardware matters, a buyer needs a supplier that publishes batch-level third-party analysis, material that arrives with intact identity and purity documentation, a storage plan appropriate to lyophilized peptides, and an inventory log that ties every vial to a batch number and a certificate of analysis. Real Peptides supplies both compounds as research-use-only materials to businesses through its Wholesale Partner Program, tested to 99%+ HPLC purity with publicly verifiable COAs. Nothing below is dosing, preparation, or administration guidance — these compounds are not for human consumption.

Two research compounds that tend to be studied side by side

CJC-1295 no DAC, frequently catalogued as modified GRF 1-29, is a synthetic analogue of growth hormone-releasing hormone. Ipamorelin is a pentapeptide studied as a selective growth hormone secretagogue receptor agonist. Research literature describes them as acting through distinct receptor pathways within the somatotropic axis, which is the practical reason research programs so often acquire both: comparative and combination study designs need both inputs available from the same qualified source.

For a wholesale buyer, the takeaway is inventory planning rather than pharmacology. Both are commonly stocked as lyophilized powder in 10mg vials, both are sensitive to heat, light and moisture, and both are frequently reordered together — which means a stockout in one quietly disrupts demand for the other. Any efficacy language you encounter around these compounds should be read as preliminary; studies indicate mechanisms of action, not outcomes, and neither compound is an approved drug product. Keep your own catalog copy in the same register.

The supplier decision shapes everything downstream

You can buy excellent freezers and still run a worthless research inventory if the source material is unverified. Peptide identity is the first failure point. CJC-1295 exists in two distinct forms — with DAC and without — and they are not interchangeable in a research design. A supplier who lists them loosely, or whose COA does not name the exact sequence tested, has already told you something about their quality system.

The second failure point is testing that cannot be checked. Plenty of suppliers advertise third-party analysis but produce a COA only after the order is placed, or charge for it separately, or supply a document with no batch number linking it to the vial in your hand. A certificate you cannot match to a specific lot is a marketing asset, not a quality record. The same applies to pricing kept behind a sales call: opaque pricing usually means tiers are negotiated ad hoc rather than published, which makes your own cost modelling guesswork.

Third is fulfillment opacity. If you cannot establish where material ships from and who handled it between synthesis and your receiving desk, your chain of custody starts with a gap. Real Peptides fulfills wholesale orders from within the United States, typically shipping in 5–7 days, which keeps that chain short and documented.

What to verify before you commit to a wholesale order

Run every prospective supplier through the same checklist, and ask for evidence rather than assurances. Margins, order minimums and landed costs vary widely by category and volume, so compare on verifiable quality first and price second.

Real Peptides runs a 7-panel batch test on production lots and publishes the resulting COAs where a prospective partner can read them before spending anything. That is the specific capability the table above is testing for: verification you perform yourself rather than verification you are asked to take on faith.

Storage, labeling and segregation inside the facility

Lyophilized research peptides are stable materials when handled correctly and fragile when they aren't. The authoritative storage statement is the one issued with the batch, so build your facility plan around the COA and manufacturer documentation rather than around forum consensus. In general terms, lyophilized peptide powder is kept cold, dry, and shielded from light, with long-term holding colder than working stock. Repeated temperature cycling is the enemy; a dedicated unit with a logged thermometer beats a shared appliance that gets opened forty times a day.

Segregation matters as much as temperature. Research materials should be physically separated from every other category of inventory, with access limited to named personnel. Every unit carries research-use-only labeling, and that labeling should survive your internal handling — relabeling, decanting or repackaging into unmarked containers destroys the traceability you paid for.

Receiving is where most inventory records go wrong. Build a short, mandatory inspection at intake: confirm the compound name and form, record the lot number, check seal and vial integrity, note the condition on arrival, and pull the matching COA into your file before the material goes into storage. It takes a few minutes per shipment and it is the only point at which a discrepancy is cheap to resolve.

Documentation, and the questions that belong with your attorney

A defensible research inventory is really a set of five records: a receiving log, a batch register linking lot numbers to COAs, a storage and temperature log, a usage log, and a disposal record. None of that requires specialist software. It does require that entries are made contemporaneously and that COAs are retained for the full life of the lot and beyond. If you are ever asked to demonstrate that a specific vial came from a tested batch, these records are the answer.

The legal layer sits on top, and it is not something an article can settle for you. Whether your entity may purchase, hold, or resell research-use-only compounds depends on your business structure, your licensure, and how your state's boards and registration bodies interpret their own rules — and interpretations differ. Treat the following as questions to bring to counsel rather than conclusions: Does my entity type require any registration to hold research materials? Are there wholesale or distribution registrations that apply to resale in the states where I ship? What labeling and recordkeeping obligations attach to my role in the chain? What does my state board say about my professional license and research-use products? Where do my insurers sit on this category?

This section is informational only and is not legal advice. Get a written opinion from an attorney who knows your jurisdiction and your business model before you build a program around any assumption.

Why preparation and dosing guidance isn't part of the package

Buyers ask about reconstitution constantly, and the answer is consistent: Real Peptides does not provide dosing, preparation, or administration guidance for any catalog item, because every compound is supplied for research use only. That is a boundary, not an oversight, and any supplier willing to cross it should concern you more than one who won't.

What can be discussed is the concentration framework, which is arithmetic rather than instruction. A vial is labelled by mass — 10mg, for instance — and concentration is simply that mass expressed against a volume, giving a milligrams-per-millilitre figure. Which solvent, which volume, and which handling procedure apply are protocol decisions belonging to the qualified researcher and their institutional oversight, not to the supplier and not to the reseller. Keep your own customer-facing copy on the same side of that line: describe the compound, its purity, its batch documentation and its research context, and stop there.

What Real Peptides does differently

Real Peptides tests to 99%+ HPLC purity and runs 7-panel batch testing on production lots. The resulting certificates of analysis are publicly verifiable — a prospective partner can read the lab results for a batch without an account, a deposit, or a sales call, and match them against the lot number on the vial. That single practice resolves most of the verification checklist above before a conversation even starts.

Fulfillment is United States-based, with orders typically shipping in 5–7 days, which keeps the handling chain short and the documentation continuous. Wholesale pricing is structured in published tiers rather than negotiated case by case, so partners can model landed cost against their own volumes instead of guessing at what a competitor was quoted.

Onboarding runs through a three-step wholesale application: submit the application with your business details, complete verification, and receive tier pricing and catalog access. Both CJC-1295 no DAC and ipamorelin are standing catalog items rather than intermittent stock, which matters when two compounds are ordered as a pair and a gap in one suppresses demand for the other.

For businesses that already sell into the research space, the practical difference is auditability. When a customer, an insurer, or your own counsel asks where a batch came from and what was tested, the answer is a document you can produce on demand rather than an assurance you have to repeat.

If your business is positioned to stock research compounds and you can meet the verification requirements, the Wholesale Partner Program application at realpeptides.co is the next step — it takes a few minutes, and tier pricing is released once verification clears.

To review the individual listings and their published analysis, see CJC-1295 No DAC 10mg and Ipamorelin 10mg, or browse the wider Growth Factor & Tissue Signaling Research collection alongside related research compounds such as Tesamorelin 10mg and MOTS-c 10mg.